8th October 2014 Xeraya Capital announces SGD16M in Equity Funding in PrIME Biologics Pte Ltd
Press Release: Investment will help establish first human blood fractionation plant in South East Asia. Please click here to read this press release.
Official opening of the Gemini cGMP facility
On 8th October 2014 PrIME Biologics officially opened its revamped Gemini cGMP facility. Mr Kevin Lai, Executive Director, Biomedical Science and Consumer Business gave a speech and officially opened the Gemini cGMP facility. A copy of Mr Kevin Lai’s speech can be downloaded here. A copy of Dr Hari Nair’s speech can be downloaded here.
Dr Hari Nair Presents at 4th Bioplasma World Asia 2014 Conference
Dr Nair presented a speech at the Bioplasma World Asia 2014 Conference on 1st July 2014. Dr Nair talked to the need to develop plasma fractionation in Asia and the efforts PrIME Biologics was undertaking to address this issue. A copy of his presentation can be downloaded from this section.
1st Completion of the funding from Xeraya Capital and JP Capital
On 17th June 2014 PrIME Biologics raised S$7.4m from a subsidiary of Xeraya Capital and a subsidiary of JP Capital. This was the first of four milestone investment tranches that in total will raise S$20m to fund PrIME Biologics.
PrIME Biologics Signs the Investment Agreement with Xeraya Capital and JP Capital
On 6th May 2014 PrIME Biologics signed the Investment Agreement with Xeraya Capital and JP Capital for an investment of up to S$20m in PrIME Biologics.
PrIME Biologics signs $1m bridging loan facility
On 26th February 2014 PrIME Biologics signed a S$1m bridging loan facility with a number of external investors. This facility was used to fund PrIME Biologics and undertake a technology validation project prior to the investment by Xeraya Capital and JP Capital.
click the edit button to change this text.
PrIME Biologics starts operating as a separate Company
On the 1st December 2013 PrIME Biologics started operating as a separate company for its then parent, NuSep Holdings Ltd. From 1st December 2013 the management, funding and profit and loss of PrIME Biologics was separated from NuSep Holdings. NuSep was from this date forward a passive investor in PrIME Biologics.
NuSep signs a S$15m Term Sheet to fund PrIME Biologics
On 29th October 2013 NuSep signed a non binding term sheet for the investment by Xeraya Capital of S$15m in PrIME Biologics.
Dr Hari Nair presents at the 3rd Bioplasma World Asia 2013 Conference
On 4th September 2013 Dr Nair presented at the 3rd Bioplasma World Asia 2013 conference. A copy of this presentation can be downloaded from this section.
PrIME Biologics completes the lease for the Gemini cGMP Facility
On 10th January 2013 PrIME Biologics completed a lease with the Ascendas group for the space in which PrIME Biologics has its cGMP facility.
PrIME Biologics undertakes the first separation of Albumin in a cGMP facility
In December 2012 the staff of PrIME Biologics undertook 3 replicate separations of Human Albumin from Human Plasma in its Gemini cGMP facility.
The pilot scale cGMP PrIME Technology unit was shipped to PrIME Biologics Gemini cGMP facility
In October 2012 NuSep shipped its cGMP pilot scales PrIME Technology unit to PrIME Biologics Gemini cGMP facility.
PrIME Biologics acquires the Gemini cGMP facility
In August 2012 PrIME Biologics acquired the Gemini cGMP facility from the Luye Group.